These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 8985818)

  • 21. Long-term follow-up after successful interferon therapy of acute hepatitis C.
    Wiegand J; Jäckel E; Cornberg M; Hinrichsen H; Dietrich M; Kroeger J; Fritsch WP; Kubitschke A; Aslan N; Tillmann HL; Manns MP; Wedemeyer H
    Hepatology; 2004 Jul; 40(1):98-107. PubMed ID: 15239091
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Early loss of serum hepatitis C virus RNA can predict a sustained response to interferon therapy in patients with chronic hepatitis C.
    Karino Y; Toyota J; Sugawara M; Higashino K; Sato T; Ohmura T; Suga T; Okuuchi Y; Matsushima T
    Am J Gastroenterol; 1997 Jan; 92(1):61-5. PubMed ID: 8995939
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combination of interferon alfa-2b and ribavirin in liver transplant recipients with histological recurrent hepatitis C.
    Firpi RJ; Abdelmalek MF; Soldevila-Pico C; Reed A; Hemming A; Howard R; Van Der Werf W; Lauwers G; Liu C; Crawford JM; Davis GL; Nelson DR
    Liver Transpl; 2002 Nov; 8(11):1000-6. PubMed ID: 12424712
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment induced leucopenia in hepatitis C and Role of G-CSF in its management.
    Shafi MS; Sheikh NI; Rizvi F; Afzal M; Manzoor S
    J Coll Physicians Surg Pak; 2009 Jun; 19(6):346-9. PubMed ID: 19486571
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serum CXCL10 levels and occurrence of thyroid dysfunction in patients treated with interferon-alpha therapy for hepatitis C virus-related hepatitis.
    Rotondi M; Minelli R; Magri F; Leporati P; Romagnani P; Baroni MC; Delsignore R; Serio M; Chiovato L
    Eur J Endocrinol; 2007 Apr; 156(4):409-14. PubMed ID: 17389454
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Natural interferon alpha treatment and interferon alpha receptor 2 levels in acute hepatitis C.
    Ohata K; Yano K; Yatsuhashi H; Daikoku M; Koga M; Eguchi K; Yano M
    Dig Dis Sci; 2004 Feb; 49(2):289-94. PubMed ID: 15104372
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lymphoblastoid interferon alfa-n1 improves the long-term response to a 6-month course of treatment in chronic hepatitis C compared with recombinant interferon alfa-2b: results of an international randomized controlled trial. Clinical Advisory Group for the Hepatitis C Comparative Study.
    Farrell GC; Bacon BR; Goldin RD
    Hepatology; 1998 Apr; 27(4):1121-7. PubMed ID: 9537453
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of pegylated interferon alpha-2a therapy for chronic hepatitis C in HIV-infected patients with haemophilia.
    Zhang RF; Sun HQ; Huang Q; Wang JR; Zhang XX; Liu XN; Ma Q; Lu HZ
    Haemophilia; 2010 May; 16(3):502-7. PubMed ID: 20028427
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Usefulness of simple assays for serum concentration of hepatitis C virus RNA and HCV genotype in predicting the response of patients with chronic hepatitis C to interferon alpha 2a therapy.
    Suzuki T; Tanaka E; Matsumoto A; Urushihara A; Sodeyama T
    J Med Virol; 1995 Jun; 46(2):162-8. PubMed ID: 7636506
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Granulocytopenia after combined therapy with interferon and angiotensin- converting enzyme inhibitors: evidence for a synergistic hematologic toxicity.
    Jacquot C; Caudwell V; Belenfant X
    Am J Med; 1996 Aug; 101(2):235-6. PubMed ID: 8757368
    [No Abstract]   [Full Text] [Related]  

  • 31. Use of granulocyte macrophage colony stimulating factor alone or in combination with interferon-alpha-2b for treatment of chronic hepatitis C.
    Shiffman ML; Hofmann CM; Luketic VA; Sanyal AJ
    J Hepatol; 1998 Mar; 28(3):382-9. PubMed ID: 9551674
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pegylated interferon plus ribavirin combination therapy for chronic hepatitis C with high viral load of serum hepatitis C virus RNA, genotype 1b, discontinued on attaining sustained virological response at week 16 after onset of acute pancreatitis.
    Kim SR; Imoto S; Mita K; Taniguchi M; Sasase N; Muramatsu A; Kudo M; Kitai S; El-Shamy A; Hotta H; Hayashi Y
    Digestion; 2009; 79(1):36-9. PubMed ID: 19246919
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anti-Golgi complex antibodies during pegylated-interferon therapy for hepatitis C.
    Paraná R; Schinoni MI; de Freitas LA; Codes L; Cruz M; Andrade Z; Trepo C
    Liver Int; 2006 Nov; 26(9):1148-54. PubMed ID: 17032416
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of hepatitis C virus genotype 4 with peginterferon alfa-2a: impact of bilharziasis and fibrosis stage.
    Derbala MF; Al Kaabi SR; El Dweik NZ; Pasic F; Butt MT; Yakoob R; Al-Marri A; Amer AM; Morad N; Bener A
    World J Gastroenterol; 2006 Sep; 12(35):5692-8. PubMed ID: 17007024
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Section 13. Short-course pretransplant antiviral therapy is a feasible and effective strategy to prevent hepatitis C recurrence after liver transplantation in genotype 2 patients.
    Lin CC; Kabiling C; Chen CL; Lin YH; Liu YW; Wang CC; Hu TH; Chiu KW
    Transplantation; 2014 Apr; 97 Suppl 8():S47-53. PubMed ID: 24849835
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PEG-interferon in acute and chronic hepatitis C: a review.
    Palumbo E
    Am J Ther; 2009; 16(6):573-8. PubMed ID: 19433975
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combination therapy with interferon-alpha and ribavirin in patients with dual hepatitis B and hepatitis C virus infection.
    Hung CH; Lee CM; Lu SN; Wang JH; Tung HD; Chen CH; Changchien CS
    J Gastroenterol Hepatol; 2005 May; 20(5):727-32. PubMed ID: 15853986
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predictors of the efficacy of interferon therapy in chronic hepatitis C virus infection. Tokyo-Chiba Hepatitis Research Group.
    Shiratori Y; Kato N; Yokosuka O; Imazeki F; Hashimoto E; Hayashi N; Nakamura A; Asada M; Kuroda H; Tanaka N; Arakawa Y; Omata M
    Gastroenterology; 1997 Aug; 113(2):558-66. PubMed ID: 9247476
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation.
    Crippin JS; McCashland T; Terrault N; Sheiner P; Charlton MR
    Liver Transpl; 2002 Apr; 8(4):350-5. PubMed ID: 11965579
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Incidence of side effects during therapy with different types of alpha interferon: a randomised controlled trial comparing recombinant alpha 2b versus leukocyte interferon in the therapy of naive patients with chronic hepatitis C.
    Ascione A; De Luca M; Di Costanzo GG; Picciotto FP; Lanza AG; Canestrini C; Morisco F; Tuccillo C; Caporaso N
    Curr Pharm Des; 2002; 8(11):977-80. PubMed ID: 11945144
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.